肺动脉高压患者起始胃肠外前列环素治疗前后超声心动图变量的预后价值:一项观察性研究
该回顾性队列纳入2007至2016年起始静脉依前列醇或静脉/皮下曲前列尼尔治疗的肺动脉高压患者118例,随访至2020年5月31日,中位随访7.3年。治疗至少90天后复查超声心动图(101例,中位178天)显示右室功能、右室收缩压、右室舒张内径、左室舒张内径及三尖瓣反流严重程度五项指标改善;三尖瓣反流严重程度与心包积液与起始治疗后的生存相关,右房大小等指标与首次复查后的生存相关。
要点
- 起始静脉/皮下前列环素治疗后多项超声心动图指标改善
- 三尖瓣反流严重程度和心包积液与起始治疗后的生存相关
- 治疗至少90天后复查时右房大小等指标与生存相关,右房大小可能有助于预后评估
核心结论
- 起始静脉/皮下前列环素治疗后超声心动图变量改善,多个超声指标与生存显著相关,尤其在治疗至少90天后复查时。
- 右房大小可能对接受静脉/皮下前列环素治疗的肺动脉高压患者随访预后评估有用。
研究设计与样本
- 回顾性队列研究,纳入2007至2016年起始静脉依前列醇或静脉/皮下曲前列尼尔治疗的肺动脉高压患者,随访至2020年5月31日。
- 共纳入118例患者,中位随访7.3年;101例患者完成随访超声心动图,中位时间178天(四分位距140-273天)。
主要发现
- 1年、2年、3年生存率分别为86%、79%、69%。
- 随访超声心动图显示右室功能、右室收缩压、右室舒张内径、左室舒张内径及三尖瓣反流严重程度五项指标改善。
- 三尖瓣反流严重程度和心包积液与起始静脉/皮下治疗后的生存相关。
- 右室舒张内径、右房大小、三尖瓣反流严重程度和下腔静脉特征与首次随访后的生存相关。
- 多变量分析中,步行距离、功能分级、N末端B型利钠肽原和右房大小构成最佳生存模型。
关键数值与推荐
- 生存率:1年86%、2年79%、3年69%(N=118,中位随访7.3年)。
- 随访超声心动图中位时间178天,四分位距140-273天(101例)。
- 多变量分析中右房大小纳入最佳拟合生存模型(首次随访时评估)。
临床怎么用
- 对接受静脉/皮下前列环素治疗的肺动脉高压患者,可在治疗至少90天后复查超声心动图评估预后。
- 随访中关注右房大小、三尖瓣反流严重程度、心包积液及下腔静脉特征等超声指标。
- 结合步行距离、功能分级和N末端B型利钠肽原等指标综合判断预后。
局限性
- 为单中心回顾性队列研究,样本量118例,随访超声心动图仅101例完成。
- 研究时间跨度2007至2016年,治疗方案与当前实践可能存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Echocardiographic parameters are used as prognostic markers in patients with pulmonary arterial hypertension (PAH) receiving parenteral (IV or subcutaneous [IV/SC]) prostacyclin therapy. However, data on how posttreatment echocardiographic results associate with outcomes are limited. RESEARCH QUESTION: Are echocardiographic parameters pre- and post-parenteral prostacyclin therapy in patients with PAH associated with long-term outcomes? STUDY DESIGN AND METHODS: In this retrospective cohort study, patients with PAH initiated on IV epoprostenol or IV/SC treprostinil therapy between 2007 and 2016 were included and followed up through May 31, 2020. Survival free from transplant was assessed from the time of IV/SC prostacyclin therapy initiation and from first follow-up echocardiogram following at least 90 days of therapy. RESULTS: Patients with PAH initiated on IV/SC prostacyclin therapy (N = 118) were followed up for a median of 7.3 years. Survival was 86%, 79%, and 69% at 1, 2, and 3 years, respectively. Follow-up echocardiogram in 101 patients (median, 178 days; interquartile range, 140-273 days) showed improvement in five echocardiographic measures: right ventricular function, right ventricular systolic pressure, right ventricular diastolic diameter, left ventricular diastolic diameter, and tricuspid regurgitation (TR) severity. TR severity and pericardial effusion were associated with survival from IV/SC therapy initiation, whereas right ventricular diastolic diameter, right atrial (RA) size, TR severity, and inferior vena cava characteristics were associated with survival from first follow-up. In a multivariable analysis incorporating other prognostic measures at first follow-up, walk distance, functional class, N-terminal pro-B-type natriuretic peptide, and RA size resulted in the best fit model for survival. INTERPRETATION: Echocardiographic variables improved following IV/SC therapy, and multiple echocardiographic measures associated significantly with survival, particularly when reassessed after at least 90 days of therapy. RA size in particular may be useful in prognostication in follow-up of patients with PAH on IV/SC therapy.
引用
- Shah T, Manthena P, Patel C, et al. Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy: An Observational Study. Chest. 2022. PMID: 35460641. doi:10.1016/j.chest.2022.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。